Latest Ratios: P/E Ratio -0.9x · EV/EBITDA N/A · ROE -165.2%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $44M | $41M | $93M | $202M | $114M | $165M | $206M | $60M | — | — | — |
| Enterprise Value | $21M | $18M | $73M | $177M | $77M | $105M | $185M | $53M | — | — | — |
| P/E Ratio → | -0.90 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 885.29 | 829.46 | 6652.75 | 1306.23 | 303.90 | 909.04 | 18766.67 | — | — | — | — |
| P/B Ratio | 1.88 | 1.76 | 2.90 | 5.31 | 1.89 | 2.05 | 5.33 | 2.52 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 355.12 | 5185.75 | 1142.29 | 205.39 | 579.89 | 16784.21 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | -61738.0% | -61738.0% | -304535.7% | -19187.7% | -6938.8% | -16106.6% | -111163.6% | — | — | — | — |
| Net Profit Margin | -91866.0% | -91866.0% | -300585.7% | -19360.0% | -7299.2% | -16762.4% | -109990.9% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -165.2% | -165.2% | -119.8% | -61.1% | -38.9% | -51.0% | -38.8% | -38.2% | -71.8% | -9.3% | — |
| ROA | -127.7% | -127.7% | -87.2% | -43.2% | -30.0% | -43.2% | -37.2% | -36.7% | -69.5% | -8.8% | -119.5% |
| ROIC | -407.4% | -407.4% | -263.3% | -124.0% | -88.7% | -116.3% | -54.4% | -35.1% | -56.4% | -8.8% | -1199.5% |
| ROCE | -109.7% | -109.7% | -120.3% | -54.4% | -31.2% | -43.4% | -39.0% | -38.5% | -71.8% | -10.9% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.01 | 0.27 | 0.25 | 0.19 | 0.00 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 712.83 |
| Net Debt / Equity | — | -1.01 | -0.64 | -0.67 | -0.61 | -0.74 | -0.56 | -0.29 | -0.01 | -0.08 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -2855.65 | 424.32 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($25M) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.55 | 3.55 | 3.14 | 2.16 | 5.92 | 18.95 | 13.51 | 11.09 | 1.03 | 6.13 | 0.75 |
| Quick Ratio | 3.55 | 3.55 | 3.14 | 2.16 | 5.92 | 20.21 | 13.51 | 1109.25 | 1.03 | 6.13 | 0.75 |
| Cash Ratio | 2.94 | 2.94 | 2.90 | 1.94 | 4.78 | 17.16 | 12.37 | 9.99 | 0.23 | 4.43 | 0.24 |
| Asset Turnover | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 33149.30 | 36734.64 | 5750.52 | 8257.39 | 11099.23 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.0% | — | — | — |
| Shares Outstanding | — | $27M | $20M | $18M | $18M | $16M | $12M | $10M | $11M | $11M | $5M |
Clinical trial funding shortfall
According to recent market data, INMB trades at a P/S ratio of 755.02, a figure that appears disconnected from fundamental performance and suggests investors are pricing in speculative clinical success rather than current financial output, as noted in the company's latest quarterly valuation metrics.
The extreme P/S multiple reflects the market's focus on the potential of the DN-TNF platform rather than any near-term revenue generation. Investors should monitor whether this valuation can be sustained as the company approaches critical data readouts, as any delay in clinical milestones may lead to significant multiple compression.
Based on reported financial statements, INMB's ROIC has consistently trended in negative territory, reaching -66.8% in 2025Q1, which highlights the structural difficulty of generating returns on invested capital while the company remains in a pre-commercial, high-expenditure phase of its clinical development lifecycle.
The persistent negative ROIC is a direct consequence of heavy R&D spending relative to the lack of commercialized products. This trend suggests that capital is being consumed to build the intellectual property moat rather than to generate immediate economic value, which is typical for the biotechnology sector.
As reported in recent filings, the company's current ratio has fluctuated between 1.71 and 4.24 over the last ten quarters, indicating that while short-term liquidity appears adequate, the rapid depletion of cash reserves necessitates frequent capital raises to maintain ongoing clinical trial operations.
The volatility in the current ratio suggests that liquidity is highly sensitive to the timing of equity financing rounds. Investors should be wary of the company's reliance on external capital, as any disruption in the equity markets could severely impact the firm's ability to complete its Phase 2 trials.
Based on comparative analysis, INMB's P/B ratio of 1.60 sits at a discount to peers like ACADIA Pharmaceuticals, which trades at 3.54, potentially signaling market skepticism regarding the company's smaller balance sheet and the inherent risks associated with its multi-platform clinical development strategy.
This valuation gap may be structural, reflecting the market's preference for companies with more advanced commercial pipelines or larger cash buffers. The discount warrants further investigation into whether the market is underestimating the potential of the DN-TNF platform compared to the more established assets of its peers.
As noted in financial analysis, the P/S ratio is frequently misapplied to INMB, as the company's negligible revenue base renders this metric functionally useless for assessing intrinsic value, leading to distorted perceptions of the company's actual economic health and its long-term growth prospects.
Instead of relying on P/S, investors should focus on the 'Cash Burn Rate' and 'Clinical Milestone Progress' as more accurate indicators of value. Using revenue-based multiples in a pre-commercial biotech context obscures the reality that the company is currently a research-driven entity rather than a commercial enterprise.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INMB stock.
INmune Bio, Inc.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
INmune Bio, Inc.'s return on equity (ROE) is -165.2%. The historical average is -66.0%.
Based on historical data, INmune Bio, Inc. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
INmune Bio, Inc. has 100.0% gross margin and -61738.0% operating margin.